We are live on !
Find out more
Patient Square Capital Portfolio holdings
AUM
$646M
Turnover
51.43%
1-Year Est. Return
291.07%
This Fund
S&P 500
This Quarter Est. Return
+24.89%
1 Year Est. Return
+291.07%
3 Year Est. Return
+328.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$646M
AUM Growth
+$81.9M
(+15%)
Cap. Flow
-$14.5M
Cap. Flow % of AUM
Cap. Flow %
-2.25%
Top 10 Holdings %
Top 10 Hldgs %
80.13%
Holding
35
New
6
Increased
9
Reduced
8
Closed
12
Avg Time Held
0.8
years
Top 10 Avg Time Held
0.7
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$40.3M |
| 2 |
United Therapeutics
UTHR
|
+$20.9M |
| 3 |
BioNTech
BNTX
|
+$12.7M |
| 4 |
Abivax
ABVX
|
+$9.6M |
| 5 |
Inventiva
IVA
|
+$9.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$25.8M |
| 2 |
Legend Biotech
LEGN
|
+$17.9M |
| 3 |
Nektar Therapeutics
NKTR
|
+$15.1M |
| 4 |
argenx
ARGX
|
+$11.3M |
| 5 |
Celcuity
CELC
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$26.2B
| $284M | 43.97% |
8,020,928
-145,119
| -2% | -$4.29M |
2022 Q4
14 quarters
|
|
|
2
Revolution Medicines
RVMD
$40.8B
| $51.7M | 8.01% |
+276,000
| New | +$40.3M |
2026 Q2
0 quarters
|
|
3
Mirum Pharmaceuticals
MIRM
$5.54B
| $30.5M | 4.72% |
260,500
+30,500
| +13% | +$3.06M |
2024 Q4
6 quarters
|
|
|
4
Abivax
ABVX
$7.39B
| $27.5M | 4.26% |
206,500
+85,255
| +70% | +$9.6M |
2025 Q3
3 quarters
|
|
5
BeOne Medicines Ltd
ONC
$41.1B
| $25.7M | 3.97% |
90,020
+9,478
| +12% | +$2.79M |
2025 Q4
2 quarters
|
|
6
Pharvaris
PHVS
$2.35B
| $23.2M | 3.6% |
671,209
+178,209
| +36% | +$5.39M |
2024 Q3
7 quarters
|
|
|
7
argenx
ARGX
$55.6B
| $21.3M | 3.31% |
23,000
-13,718
| -37% | -$11.3M |
2025 Q2
4 quarters
|
|
|
8
United Therapeutics
UTHR
$25.5B
| $20.1M | 3.12% |
+37,120
| New | +$20.9M |
2026 Q2
0 quarters
|
|
9
Belite Bio
BLTE
$6.23B
| $16.9M | 2.62% |
110,000
-6,684
| -6% | -$1.02M |
2026 Q1
1 quarter
|
|
10
Cogent Biosciences
COGT
$5.22B
| $16.4M | 2.55% |
425,000
-171,000
| -29% | -$5.98M |
2025 Q4
2 quarters
|
|
11
DBV Technologies S.A. American Depositary Shares
DBVT
$573M
| $14.9M | 2.31% |
909,474
+215,940
| +31% | +$4.07M |
2025 Q4
2 quarters
|
|
12
Xenon Pharmaceuticals
XENE
$3.69B
| $13.3M | 2.06% |
220,000
-7,000
| -3% | -$389K |
2025 Q4
2 quarters
|
|
|
13
BioNTech
BNTX
$22B
| $12.5M | 1.94% |
+134,429
| New | +$12.7M |
2026 Q2
0 quarters
|
|
14
Arcus Biosciences
RCUS
$2.28B
| $11M | 1.7% |
355,800
+160,800
| +82% | +$3.97M |
2025 Q4
2 quarters
|
|
15
Enliven Therapeutics
ELVN
$3.25B
| $10.8M | 1.67% |
212,500
+12,500
| +6% | +$531K |
2024 Q3
7 quarters
|
|
16
Dianthus Therapeutics
DNTH
$4.6B
| $10.5M | 1.63% |
108,000
+14,118
| +15% | +$1.23M |
2025 Q3
3 quarters
|
|
17
Allogene Therapeutics
ALLO
$377M
| $10.5M | 1.63% |
5,050,000
+1,600,000
| +46% | +$3.51M |
2024 Q4
6 quarters
|
|
18
EyePoint Inc
EYPT
$32.3M
| $10.3M | 1.6% |
720,000
-75,000
| -9% | -$1M |
2024 Q3
7 quarters
|
|
19
Arcutis Biotherapeutics
ARQT
$4.03B
| $9.7M | 1.5% |
370,000
-30,645
| -8% | -$714K |
2025 Q4
2 quarters
|
|
20
C4 Therapeutics
CCCC
$405M
| $7.51M | 1.16% |
+1,608,815
| New | +$5.5M |
2026 Q2
0 quarters
|
|
|
21
Inventiva
IVA
$917M
| $7.44M | 1.15% |
+1,967,171
| New | +$9.45M |
2026 Q2
0 quarters
|
|
22
Kymera Therapeutics
KYMR
$10.9B
| $5.45M | 0.84% |
47,500
-52,500
| -53% | -$4.51M |
2025 Q1
5 quarters
|
|
23
Faeth Therapeutics
FTH
$483M
| $4.38M | 0.68% |
+175,050
| New | +$4.05M |
2026 Q2
0 quarters
|
|
24
Assembly Biosciences
ASMB
$398M
| – | – |
-136,315
| Closed | -$3.78M | – |
|
25
Perspective Therapeutics
CATX
$123M
| – | – |
-1,625,000
| Closed | -$6.78M | – |
|
Similar funds
JCP
Patient Square Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Patient Square Capital held 35 positions worth $646M, up 15% from $564M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
Patient Square Capital's Q2 2026 filing shows 6 new, 9 increased, 8 reduced and 12 closed positions. Its largest new stake was Revolution Medicines: 276,000 shares worth $51.7M. The largest sale was Insmed, an estimated $25.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Patient Square Capital's largest Q2 2026 buy was Revolution Medicines: 276,000 shares worth $51.7M.
- Patient Square Capital added most to Abivax in Q2 2026, an estimated $9.6M increase.
- Patient Square Capital's biggest Q2 2026 reduction was argenx, cutting an estimated $11.3M.
- Patient Square Capital fully exited Insmed in Q2 2026, selling an estimated $25.8M.
- Patient Square Capital's ten largest holdings make up 80% of its $646M portfolio in Q2 2026.
- Patient Square Capital opened 6 new positions and closed 12 in Q2 2026.
- Patient Square Capital's portfolio value rose 15% quarter-over-quarter to $646M.
Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.